Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Germo Gericke

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|May 13, 2021
A perspective on the EANM procedure guidelines for radionuclide therapy with <sup>177</sup>Lu-labelled PSMA-ligandsGermo Gericke
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2026
Targeted Radiopharmaceutical Therapy: Advances, Investment Dynamics, and Future Directions-Part 1Catello Somma, Richard Zimmermann, Germo Gericke, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2026
Targeted Radiopharmaceutical Therapy: Advances, Investment Dynamics, and Future Directions-Part 2Catello Somma, Richard Zimmermann, Germo Gericke, et al.
Endocrine|November 6, 2021
Combination of pasireotide and octreotide: effects on GH and IGF-I secretion and glucose metabolism in healthy volunteersLibuse Tauchmanova, Astrid Breitschaft, Geoffrey Holder, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 13, 2025
Dosimetry of [<sup>177</sup>Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 TrialLisa Bodei, Marta Cremonesi, Mahila Ferrari, et al.
The Lancet. Oncology|November 18, 2021
<sup>177</sup>Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trialJonathan R Strosberg, Martyn E Caplin, Pamela L Kunz, et al.
The New England Journal of Medicine|June 23, 2021
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate CancerOliver Sartor, Johann de Bono, Kim N Chi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 4, 2020
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with <sup>177</sup>Lu-Dotatate: an analysis of the NETTER-1 studyJonathan Strosberg, Pamela L Kunz, Andrew Hendifar, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
European Journal of Nuclear Medicine and Molecular Imaging|May 13, 2021
A perspective on the EANM procedure guidelines for radionuclide therapy with <sup>177</sup>Lu-labelled PSMA-ligandsGermo Gericke
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2026
Targeted Radiopharmaceutical Therapy: Advances, Investment Dynamics, and Future Directions-Part 1Catello Somma, Richard Zimmermann, Germo Gericke, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 21, 2026
Targeted Radiopharmaceutical Therapy: Advances, Investment Dynamics, and Future Directions-Part 2Catello Somma, Richard Zimmermann, Germo Gericke, et al.
Endocrine|November 6, 2021
Combination of pasireotide and octreotide: effects on GH and IGF-I secretion and glucose metabolism in healthy volunteersLibuse Tauchmanova, Astrid Breitschaft, Geoffrey Holder, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 13, 2025
Dosimetry of [<sup>177</sup>Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 TrialLisa Bodei, Marta Cremonesi, Mahila Ferrari, et al.
The Lancet. Oncology|November 18, 2021
<sup>177</sup>Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trialJonathan R Strosberg, Martyn E Caplin, Pamela L Kunz, et al.
The New England Journal of Medicine|June 23, 2021
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate CancerOliver Sartor, Johann de Bono, Kim N Chi, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 4, 2020
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with <sup>177</sup>Lu-Dotatate: an analysis of the NETTER-1 studyJonathan Strosberg, Pamela L Kunz, Andrew Hendifar, et al.
Pageof 1